Clinical Study on the Safety and Efficacy of JWK002 Injection Administered as a Single Subretinal Injection in Subjects With X-linked Retinoschisis.
In: Cancer Gene Therapy Week, 2024-04-15, S. 19-19
serialPeriodical
Zugriff:
This document provides information about a clinical trial in China evaluating the safety and effectiveness of JWK002 gene therapy for the treatment of X-linked retinoschisis (XLRS), a genetic eye condition. The trial is currently in the early phase and is non-randomized. It will enroll participants aged 5-18 years old who will receive a sub-retinal injection of JWK002. The primary outcome measures of the trial include assessing the safety of the treatment and measuring visual acuity and retinal structure. The trial is expected to be completed by December 2029 and has specific eligibility criteria for participants. For further information, the primary contact is Licong Liang. [Extracted from the article]
Copyright of Cancer Gene Therapy Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Clinical Study on the Safety and Efficacy of JWK002 Injection Administered as a Single Subretinal Injection in Subjects With X-linked Retinoschisis.
|
---|---|
Zeitschrift: | Cancer Gene Therapy Week, 2024-04-15, S. 19-19 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1543-6837 (print) |
Schlagwort: |
|
Sonstiges: |
|